At the news
? BULLISHIMPACT 7/10 8-K filed Feb 25, 2026 at 16:01 ET
Xencor reported financial results for Q4 and full year 2025, showing increased revenue and improved net loss compared to 2024, driven by collaboration and royalty income. The company highlighted clinical progress across its pipeline, including XmAb819 and XmAb541 in oncology and XmAb942 in inflammatory bowel disease, with key data expected in 2026. Xencor maintains a strong cash position and expects to end 2026 with $400–430 million in cash, sufficient to fund operations through 2028.
- Revenue increased 13.7% YoY to $125.6 million in 2025, driven by Alexion and Incyte license agreements.
- Net loss narrowed significantly to $91.9 million ($1.24 EPS) in 2025 vs. $232.6 million ($3.58 EPS) in 2024.
- Cash, cash equivalents, and marketable securities totaled $610.8 million as of December 31, 2025.
- Xencor expects to end 2026 with $400–430 million in cash and sufficient runway through 2028.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access